|
1
|
Darroch JE: Trends in contraceptive use.
Contraception. 87:259–263. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tandulwadkar S, Gupta S, Singh A, Mishra S
and Singhania S: Medroxyprogesterone acetate versus
gonadotropin-releasing hormone antagonist for the prevention of
premature luteinizing hormone surge in hyper-responder women
undergoing controlled ovarian stimulation for IVF/ICSI Cycles. JBRA
Assist Reprod. 27(15)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bigrigg A, Evans M, Gbolade B, Newton J,
Pollard L, Szarewski A, Thomas C and Walling M: Depo Provera.
Position paper on clinical use, effectiveness and side effects. Br
J Fam Plann. 25:69–76. 1999.PubMed/NCBI
|
|
4
|
Phung MT, Lee AW, Wu AH, Berchuck A, Cho
KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, et al:
Depot-medroxyprogesterone acetate use is associated with decreased
risk of ovarian cancer: The mounting evidence of a protective role
of progestins. Cancer Epidemiol Biomarkers Prev. 30:927–935.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Heffron R, Achilles SL, Dorflinger LJ,
Hapgood JP, Kiarie J, Polis CB and Steyn PS: Pharmacokinetic,
biologic and epidemiologic differences in MPA-and NET-based
progestin-only injectable contraceptives relative to the potential
impact on HIV acquisition in women. Contraception. 99:199–204.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Abed MN, Qazzaz ME and Alassaf FA:
Investigating the nephrotoxic effects of medroxyprogesterone in
female albino rats. Ukr J Nephrol Dial. 2024:25–33. 2024.
|
|
7
|
Sathe A and Gerriets V:
Medroxyprogesterone. In: StatPearls. StatPearls Publishing,
Treasure Island, FL, 2024. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559192/.
|
|
8
|
Baik SH, Baye F and McDonald CJ: Effects
of hormone therapy on survival, cancer, cardiovascular and dementia
risks in 7 million menopausal women over age 65: A retrospective
observational study. medRxiv: May 26, 2022 (Epub ahead of
print).
|
|
9
|
Ramazonovna KS: Differential diagnosis and
treatment of depressive disorders in women during menopause. Eur J
Innov Nonform Educ. 2:23–30. 2022.
|
|
10
|
Hosseinzadeh P and Wild R: Role of lipid
management in women's health preventive care. Obstet Gynecol Clin.
48:173–191. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Özcan Ö, Den Elzen WPJ, Hillebrand JJ, Den
Heijer M, Van Loendersloot LL, Fischer J, Hamer H, de Jonge R and
Heijboer AC: The effect of hormonal contraceptive therapy on
clinical laboratory parameters: A literature review. Clin Chem Lab
Med. 62:18–40. 2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Trinh A, Vyas A, Roselle A, Velu D, Hota L
and Kadiyala M: Contraception and Cardiovascular Effects: What
Should the Cardiologist Know? Curr Cardiol Rep. 25:1489–1498.
2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Björnsson ES: Drug-induced cholestasis.
In: Cholestatic Liver Disease. Carey EJ and Lindor KD (eds).
Springer, New York, NY, pp13-31, 2014. Available from: https://doi.org/10.1007/978-1-4939-1013-7_2.
|
|
14
|
Kapp N: WHO provider brief on hormonal
contraception and liver disease. Contraception. 80:325–326.
2009.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sitruk-Ware R: Reprint of pharmacological
profile of progestins. Maturitas. 61:151–157. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mukherjea M, Mukherjee P, Biswas R,
Chakraborty AS and Kushari J: Effect of medroxyprogesterone acetate
contraception on human serum enzymes. Int J Fertil. 26:35–39.
1981.PubMed/NCBI
|
|
17
|
Connolly TJ and Zuckerman AL:
Contraception in the patient with liver disease. Semin Perinatol.
22:178–182. 1998.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Curtis KM, Tepper NK, Jatlaoui TC,
Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP,
Jamieson DJ and Whiteman MK: US medical eligibility criteria for
contraceptive use, 2016. MMWR Recomm Rep. 65:1–103. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Itriyeva K: Use of Long-acting reversible
contraception (LARC) and the Depo-provera shot in adolescents. Curr
Probl Pediatr Adolesc Health Care. 48:321–332. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sathe A and Gerriets V:
Medroxyprogesterone. In: StatPearls. StatPearls Publishing,
Treasure Island, FL, 2022. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559192/.
|
|
21
|
Abd-Elkareem M, Alnasser SM, Meshal A,
Abdullah RI and Ali AU: The effect of Norethisterone acetate on the
uterus of albino rats: Histological, histochemical and
ultrastructure study. BMC Vet Res. 20(384)2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chisholm NC and Juraska JM: Effects of
long-term treatment with estrogen and medroxyprogesterone acetate
on synapse number in the medial prefrontal cortex of aged female
rats. Menopause. 19:804–811. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chane E, Wondifraw H, Hadgu R and Fasil A:
Assessment of liver function tests of women taking hormonal
contraceptives at University of Gondar comprehensive specialized
hospital and Family Guidance Association of Gondar (FGAE), 2022; a
comparative cross-sectional study. PLoS One.
18(e0289746)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ebele JI, Emeka EN, Ignatius CM, Peace UN
and Ebele E: Effects of duration of use of hormonal contraceptives
on liver function. Res J Med Sci. 3:52–55. 2009.
|
|
25
|
Faddah L, Al-Rehany M, Abdel-Hamid N and
Bakeet A: Oxidative stress, lipid profile and liver functions in
average Egyptian long term depo medroxy progesterone acetate (DMPA)
users. Molecules. 10:1145–1152. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Iluz-Freundlich D, Zhang M, Uhanova J and
Minuk GY: The relative expression of hepatocellular and cholestatic
liver enzymes in adult patients with liver disease. Ann Hepatol.
19:204–208. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ribeiro AJS, Yang X, Patel V, Madabushi R
and Strauss DG: Liver microphysiological systems for predicting and
evaluating drug effects. Clin Pharmacol Ther. 106:139–147.
2019.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Kowalska K, Ściskalska M, Bizoń A,
Śliwińska-Mossoń M and Milnerowicz H: Influence of oral
contraceptives on lipid profile and paraoxonase and commonly
hepatic enzymes activities. J Clin Lab Anal.
32(e22194)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rahim SA: Activities of some liver enzymes
in serum of woman receiving oral contraceptives, injection and
Cu-IUD. Eur Asian J Biosci: 14, 2020.
|
|
30
|
Taheri M, Rahimi M, Naderi M, Ghavami S,
Mokhtari M, Rashidi H and Hashemi M: Effects of a subdermal
levonorgestrel contraceptive implant (Norplant) on serum
cholesterol, triglycerides, ALT and AST in Iranian women.
Contraception. 73:56–58. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Oh RC, Hustead TR, Ali SM and Pantsari MW:
Mildly elevated liver transaminase levels: Causes and evaluation.
Am Fam Physician. 96:709–715. 2017.PubMed/NCBI
|
|
32
|
Prati D, Taioli E, Zanella A, Torre ED,
Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S,
et al: Updated definitions of healthy ranges for serum alanine
aminotransferase levels. Ann Intern Med. 137:1–10. 2002.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Shosha HM, Ebaid HM, Toraih EA, Abdelrazek
HMA and Elrayess RA: Effect of monosodium glutamate on fetal
development and progesterone level in pregnant Wistar Albino rats.
Environ Sci Pollut Res. 30:49779–49797. 2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Coombes Z, Plant K, Freire C, Basit AW,
Butler P, Conlan RS and Gonzalez D: Progesterone metabolism by
human and rat hepatic and intestinal tissue. Pharmaceutics.
13(1707)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Serfaty D: Update on the contraceptive
contraindications. J Gynecol Obstet Hum Reprod. 48:297–307.
2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Egoro ET, Tokoni OG and Anakwe CS: Studies
on some plasma biochemical parameters in short and long term users
of oral contraceptives containing lower doses of estrogen and
progestin composition in Lagos, Nigeria. Health (NY). 1(2)2018.
|
|
37
|
Onyesom I, Osioma E, Etagar E and Ofili M:
Activities of some liver enzymes in serum of humans receiving DMPA
and CUPID contraceptives. Sch J App Med Sci. 1:62–64. 2013.
|
|
38
|
Bakry S and Abu-Shaeir W: Electrophoretic
and histopathologica l studies on adult female rats treated with
depo-provera (DMPA). Aust J Basic Appl Sci. 4:61–70. 2010.
|
|
39
|
Ahmed O, Robinson MW and O'Farrelly C:
Inflammatory processes in the liver: Divergent roles in homeostasis
and pathology. Cell Mol Immunol. 18:1375–1386. 2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Masama C, Jarkas DA, Thaw E, Daneshmend
AZ, Franklyn SI, Beaurepaire C and McQuaid RJ: Hormone
contraceptive use in young women: Altered mood states,
neuroendocrine and inflammatory biomarkers. Horm Behav.
144(105229)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Chen P, Yao L, Yuan M, Wang Z, Zhang Q,
Jiang Y and Li L: Mitochondrial dysfunction: A promising
therapeutic target for liver diseases. Genes Dis.
11(101115)2024.PubMed/NCBI View Article : Google Scholar
|
